Project Number 3R01AG051596-03S1 Agency/Funding Organization NIA Funding Year 2019 View Full Project Details for A double-blinded; randomized; controlled phase 2a safety; proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease. Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) l. Growth Factors and Hormones Researcher and Organization Principal Investigator WINDISCH, MANFRED Principal Investigator First Name MANFRED Principal Investigator Last Name WINDISCH Awardee Organization PHARMATROPHIX, INC. Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional) FY Overall Cost $245,000 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M Related Resources Clinical Trial Study of LM11A-31-BHS in Mild-moderate AD Patients
